David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Lymphoma

Simon Rule, MD

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Lymphoma

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD, on B-Cell NHL and CLL: Clinical Trial Results on T-Cell Therapy

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Cameron J. Turtle, MBBS, PhD, of the Fred Hutchinson Cancer Research Center, discuss anti-CD19 chimeric antigen receptor-modified T-cell therapy and clinical outcome (Abstract 184).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).

Lymphoma

Jonathon B. Cohen, MD

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).

Oct

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD, on B-Cell NHL and CLL: Clinical Trial Results on T-Cell Therapy

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

Jonathon Cohen, MD, on Deferring MCL Treatment

Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy

ASCO Remembers Rachna Shroff Expert in Gastrointestinal Cancers

Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project

Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC

Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC